I think the more interesting part of Injective right now isn't just the ETF narrative.
It's the direction the entire network is taking.
Three U.S. ETF filings are already tied to $INJ , while Eric Chen expects the timeline to be sooner than 2027.
At the same time, Injective has:
→ SEC-registered transfer agent infrastructure
→ Meridian live for institutional tokenization and settlement
→ INJ MiCA whitepaper finalized in Europe
→ Ongoing work with financial institutions around payments and tokenization
Put together, this looks less like a single catalyst and more like a broader push to connect traditional finance with onchain infrastructure.
The important question for me is no longer simply:
“Will institutions come to Injective?”
It's whether Injective can become part of the infrastructure they actually use once they do.
And that is a much bigger opportunity for the $INJ ecosystem.
This is information, not investment advice.
It's the direction the entire network is taking.
Three U.S. ETF filings are already tied to $INJ , while Eric Chen expects the timeline to be sooner than 2027.
At the same time, Injective has:
→ SEC-registered transfer agent infrastructure
→ Meridian live for institutional tokenization and settlement
→ INJ MiCA whitepaper finalized in Europe
→ Ongoing work with financial institutions around payments and tokenization
Put together, this looks less like a single catalyst and more like a broader push to connect traditional finance with onchain infrastructure.
The important question for me is no longer simply:
“Will institutions come to Injective?”
It's whether Injective can become part of the infrastructure they actually use once they do.
And that is a much bigger opportunity for the $INJ ecosystem.
This is information, not investment advice.